Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report
- 1 January 1985
Abstract
The ototoxicity associated with long-term cisplatin therapy in gynecologic cancer patients was investigated. Twenty-three of 31 patients developed hearing loss and 21 patients reported the onset of tinnitus. The hearing loss was bilateral, cochlear, and permanent. The tinnitus was transient and not predictive of change in hearing level. The likelihood of developing hearing loss appeared to be greatest in patients older than 40 years and in patients with preexisting hearing loss. The amount of change did not appear to be related to the degree of preexisting hearing loss.This publication has 13 references indexed in Scilit:
- Ototoxicity associated with cis-platinum in three chemotherapy multi-drug regimensCancer, 1983
- Ototoxicity of the Anticancer Drug Cisplatin:An Experimental StudyActa Oto-Laryngologica, 1982
- cis-Platinum in gynecologic cancerAmerican Journal of Obstetrics and Gynecology, 1981
- Auditory toxicity effects of long‐term cis‐dichlorodiammineplatinum II therapy in genitourinary cancer patientsJournal of Surgical Oncology, 1981
- CISPLATIN: A CLINICAL OVERVIEWPublished by Elsevier ,1980
- The Role of cis-Platinum in Solid-Tumor TherapyNew England Journal of Medicine, 1979
- cis-Platinum OtotoxicityClinical Toxicology, 1978
- Preliminary clinical experience withcis-diamminedichloroplatinum (II) (NSC 119875, CACP)Cancer, 1972
- Combined Effect of Noise and Neomycin on the CochleaActa Oto-Laryngologica, 1972
- Combined Effects of Noise and KanamycinAnnals of Otology, Rhinology & Laryngology, 1971